Dr Francesco Lanfranchi speaks to ecancer about a secondary analysis of the PRECISE-MDT Study.

The study examines metastasis-directed therapy for oligometastatic prostate cancer, revealing better outcomes than surveillance.

It analyses data from over 400 patients and compares imaging techniques, highlighting the advantages of PSMA PET over Fluor Coline PET.

The research also explores the effectiveness of different PSMA tracers and ongoing clinical trials combining MDT with lutetium PSMA radioligand therapy, suggesting areas for future investigation.